Navigation Links
ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors
Date:1/3/2012

EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Julie H. McHugh to its board of directors.

Ms. McHugh brings a wealth of pharmaceutical and health care industry experience and leadership to ViroPharma's Board of Directors.  She is currently the chief operating officer of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  Prior to joining Endo, Ms. McHugh was chief executive officer of Nora Therapeutics, Inc., a biotech company focused on the treatment of infertility disorders.  Prior to joining Nora Therapeutics, she was company group chairman for Johnson & Johnson's Worldwide Virology Business Unit and prior to this role she served as president of Centocor, Inc., a J&J subsidiary.

Ms. McHugh received a Bachelor of Science degree from Pennsylvania State University and a Masters of Business Administration degree from St. Joseph's University.  She currently serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University.  Ms McHugh also currently serves on the Board of Directors of Biotechnology Industry Association (BIO), New England Health Institute (NEHI) and the Nathaniel Adamczyk Foundation.  Ms. McHugh served in 2009 as Chairman of the Board of Directors for the Pennsylvania Biotech Association.

"We are very enthusiastic about the addition of Julie to our board," commented Vincent Milano, president and chief executive officer of ViroPharma.  "Julie's experience and insight gained from years of pharmaceutical leadership at a number of successful organizations will play a critical role in helping guide our company through our next levels of growth and achievement." 

"I am excited to have the opportunity to serve on the board of directors of ViroPharma; I am impressed by the success that the company has achieved and look forward to taking part in guiding the company towards future growth and successes in the years ahead," commented Ms. McHugh.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, adrenal insufficiency, and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

 


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma
2. ViroPharma Announces Approval of Modernized Labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules
3. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
4. ViroPharma to Participate in Two November Healthcare Investor Conferences
5. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
6. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
7. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. ViroPharma Announces Additional Securities Repurchase Program
10. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
11. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
(Date:2/11/2016)... Feb. 11, 2016  AfterPill.com is reporting that this ... abstinence for all women who are at risk of ... each year and raises the risks of unprotected sex ... --> According to the Guttmacher Institute, there are ... of child-bearing age, who have sex without the intention ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Care.” , The print component of “Revolutionizing Cancer Care” is distributed ... York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 copies and ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported about ... president has access to health and wellness resources most Americans could ever dream of ... individual has a schedule as frenetic as the U.S. President. , In honor ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not ... Peety PoppersTM series, sign language translation is featured in the top right of the ... Peety PoppersTM lessons has a sign language translator to teach kids the game and ...
(Date:2/11/2016)... ... 11, 2016 , ... “ HEALING MIND : Five Steps to Ultimate ... by Balboa Press) teaches readers how to become their own therapist. Providing a useful ... McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s inner child using ...
(Date:2/11/2016)... ... 11, 2016 , ... Dr. Sadati’s recent feature in Allure ... with performing procedures, the magazine also highlights that Dr. Sadati has pioneered new ... the most common procedures he performs is his natural facelift. “As people age, ...
Breaking Medicine News(10 mins):